The Firm represented Blau Farmacêutica S.A. (“Blau”) in connection with the initial public offering of 27,299,078 of its common shares on the São Paulo Stock Exchange (“B3”), which raised approximately R$1.1 billion.
The common shares were offered to qualified institutional buyers in the United States under Rule 144A and to non-U.S. persons in reliance on Regulation S. The shares of Blau will trade on the B3 under the ticker symbol “BLAU3.”
Blau has more than 30 years of experience in the pharmaceutical industry and is a pioneer in biotechnology in Brazil, with a portfolio of its own complex pharmaceutical products. Blau focuses on the production of biological, specialty and oncology drugs, and has a wide portfolio of injectable drugs, which are indispensable for hospitals, medical clinics and supplemental healthcare providers. Its products are sold to more than 7,000 hospital chains, 5,000 hospitals and clinics, 300 oncology clinics and 300 nephrology centers.
The Simpson Thacher team included Grenfel S. Calheiros and Marcelo B. Lorenzen (Capital Markets); and Jonathan Cantor and Edward Grais (Tax).